Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study aims to unravel fatigue in common nerve disease

NCT ID NCT07066683

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looks at fatigue in people with Charcot-Marie-Tooth type 1A (CMT1A), a nerve disorder affecting arms and legs. Researchers will compare 22 patients with 22 healthy volunteers to measure how fatigue affects walking and balance. They use tests like muscle strength measurements and questionnaires to understand both perceived tiredness and physical fatigability.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could lead to better understanding of fatigue in CMT1A, helping design future treatments or therapies to improve mobility and quality of life.
What could go wrong
This is a small pilot study (44 participants) that only observes and measures, not testing a treatment. Results may not apply to all CMT1A patients or lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for patients: * Age ≥ 18 years and \< 75 years * Patient with mCMT1A confirmed by genetic analysis (based on data recorded in the patient file) * Patient able to walk a minimum of 200 metres without a break, with or without equipment and/or technical aids (collected during questioning) * Patient able to get on and off a cycloergometer safely without assistance or with minimal assistance * Patient who has had a cardiological check-up before the stress test (ECG and cardiac ultrasound less than 6 months old) or for whom a check-up is scheduled before the inclusion * Patient affiliated to a health insurance scheme or beneficiary of such a scheme Inclusion criteria for Healthy volunteers: * Age ≥ 18 years and \< 75 years * Subject affiliated to or benefiting from a health insurance scheme * Subject who has had a cardiological work-up prior to stress testing (ECG and cardiac ultrasound less than 6 months old) or for whom a work-up is scheduled prior to the procedure. Exclusion criteria for patients: * Patients with all other forms of neuropathy (HNPP, other types of CMT, secondary neuropathies) * Patients with any of the following * An associated neurological disease other than mCMT1A * Severe joint disease of the lower limbs * Contraindication to isokinetic testing * Contraindication to an exercise stress test and exercise reconditioning program * A contraindication to Transcranial Magnetic Stimulation (TMS) : epilepsy, intracranial metallic foreign body, hearing aid or cochlear implant, unstable skull bone fracture, deafness, etc. * Patients who have undergone lower limb surgery in the 12 months prior to inclusion or for whom lower limb surgery is scheduled during the participation period. * Pregnant or breastfeeding or planning to become pregnant within the next 4 months * BMI \> 35 kg/m2 * Patient unable to give informed consent, unable to understand informed information * Subject under court protection * Subject under guardianship or curatorship * Subject in a period of exclusion (determined by a previous or current study) Exclusion criteria for healthy volunteers: * History of neurological disease * Severe joint damage in the lower limbs * Any of the following * Contraindication to isokinetic testing * A contraindication to an exercise stress test and an exercise reconditioning program * A contraindication to TMS: epilepsy, intracranial metallic foreign body, hearing aid or cochlear implant, unstable skull bone fracture, deafness, etc. * Any person who has undergone surgery on the lower limbs in the 12 months prior to inclusion, or for whom surgery on the lower limbs is scheduled during the participation period. * Pregnant or breastfeeding, or planning to become pregnant within the next 4 months * Person unable to give informed consent, unable to understand informed information * BMI \> 35 kg/m2 * Person under legal protection * Person under guardianship or curatorship * Person in a period of exclusion (determined by a previous or current study)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Charcot-Marie-Tooth type 1A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pôle de médecine physique et de réadaptation, Hôpital de Hautepierre, Strasbourg Centre de référence des maladies neuromusculaires, Institut Universitaire de Réadaptation Clémenceau, Strasbourg

    Strasbourg, 67000, France